Source comparison
Tesamorelin Ipamorelin: Stack Comparison
Tesamorelin Monotherapy GHRH receptor agonism (pituitary somatotrophs) 2.5–3.5× baseline Low (endogenous receptor cycling preserved) 8 days post-reconstitution at 2–8°C Visceral adiposity, HIV lipodystrophy, age-related GH decline Ipamorelin Monotherapy Ghreli
This comparison does not assign a generated winner or score.
- Tesamorelin Monotherapy
- GHRH receptor agonism (pituitary somatotrophs)
- 2.5–3.5× baseline
- Low (endogenous receptor cycling preserved)
- 8 days post-reconstitution at 2–8°C
- Visceral adiposity, HIV lipodystrophy, age-related GH decline
- Ipamorelin Monotherapy
- Ghrelin receptor agonism (GHS-R1a) with high selectivity
- 2.0–3.0× baseline
- Moderate (repeated dosing may reduce responsiveness after 12–16 weeks)
- 14–21 days post-reconstitution at 2–8°C
- Body composition, lean mass preservation, minimal side-effect research models
- Tesamorelin + Ipamorelin Stack
- Dual-mechanism (GHRH + ghrelin receptor) with somatostatin suppression
- 4.0–6.0× baseline
- Low (divergent pathways prevent single-receptor saturation)
- Tesamorelin limits to 8 days (reconstitute separately or in smaller batches)
- Amplified GH pulse studies, metabolic syndrome models, comparative efficacy research
- The comparison reveals why monotherapy remains standard in clinical trials. Regulatory approval pathways require single-agent evidence. But also why research applications benefit from exploring combinations. The stack's superior GH elevation occurs without proportional increases in adverse event markers, suggesting a favourable risk-to-benefit profile that warrants further investigation.